Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: ICICI Securities Limited

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	17 Sep 2026	Dr. Lal Pathlabs	Consensus Share Price Target	1924.70	1951.73	-	1.40	buy	pdf Detailed Estimates
	26 Jul 2026	Dr. Lal Pathlabs	ICICI Securities Limited	1924.70	1690.00	1759.20 (9.41%)	-12.19	Hold	pdf post cache	Broker Report Spurt in high-value testing boosts performance; valuation pricey ICICI Securities Limited Dr Lal PathLabs’ (Dr Lal) Q1FY27 performance was a beat on all fronts. The benefits of network additions are now kicking in, with patient volumes growing a strong 8.2% YoY and sample volumes up 10.7%. pdf Copy Link Share on Share on Share on Alert
	09 Jun 2026	Dr. Lal Pathlabs	Emkay	1924.70	1740.00	1575.80 (22.14%)	Target met	Buy	pdf post cache	Broker Report US NDR KTAs – Secular growth trends reaffirmed Emkay We hosted the senior management (CEO, CFO) of Dr Lal Pathlabs (DLPL) for a non-deal road show (NDR), meeting long only funds across multiple cities in the US. pdf Copy Link Share on Share on Share on Alert
	01 May 2026	Dr. Lal Pathlabs	Emkay	1924.70	1740.00	1367.20 (40.78%)	Target met	Buy	pdf post cache	Broker Report Strong quarter; upbeat FY27 guidance Emkay DLPL delivered a strong Q4FY26 print, with revenue growing 17% YoY majorly on the back of volume growth (sample/patient: 13%/8%). pdf Copy Link Share on Share on Share on Alert
	13 Apr 2026	Dr. Lal Pathlabs	FundsIndia	1924.70	1644.00	1379.80 (39.49%)	Target met	Buy	pdf post cache	Broker Report Expanding Access to Advanced Diagnostics FundsIndia Volume-Led Growth. Patient volumes recovering steadily. Expansion in Tier 2/3/4 markets. Increased tests per patient. pdf Copy Link Share on Share on Share on Alert
	17 Feb 2026	Dr. Lal Pathlabs	Geojit BNP Paribas	1924.70	1577.00	1439.00 (33.75%)	Target met	Hold	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas EBITDA rose 16.4% YoY to Rs. 179cr, and the margin expanded 140 basis points (bps) YoY to 27.2%, driven by sustained volume growth, network expansion and a favourable mix, combined with the efficient hub-and-spoke model and technology... pdf Copy Link Share on Share on Share on Alert
	02 Sep 2025	Dr. Lal Pathlabs	Geojit BNP Paribas Target	1924.70	3548.00	3228.30 (-40.38%)	Pre-Bonus/ Split	Hold	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas *over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab... pdf Copy Link Share on Share on Share on Alert
	20 Jul 2025	Dr. Lal Pathlabs	Emkay	1924.70	3100.00	3003.50 (-35.92%)	Target met	Buy	pdf post cache	Broker Report FY25 AR: Stable outlook despite leadership transition Emkay Following the slump in FY23, DLPL has registered revenue/EBITDA/PAT CAGR of 10%/19%/43%, respectively, over the last two years. pdf Copy Link Share on Share on Share on Alert
	12 May 2025	Dr. Lal Pathlabs	FundsIndia	1924.70	3269.00	2807.10 (-31.43%)	Target met	Buy	pdf post cache	Broker Report DR. LAL PATH LABS LTD. FundsIndia pdf Copy Link Share on Share on Share on Alert
	26 Apr 2025	Dr. Lal Pathlabs	Emkay Target	1924.70	3100.00	2911.20 (-33.89%)	Target met	Buy	pdf post cache	Broker Report Steady quarter; encouraging outlook Emkay DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth). pdf Copy Link Share on Share on Share on Alert
	26 Apr 2025	Dr. Lal Pathlabs	ICICI Securities Limited Target	1924.70	2900.00	2911.20 (-33.89%)	Target met	Hold	pdf post cache	Broker Report Decent quarter, limited headroom for margins expansion ICICI Securities Limited Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement. pdf Copy Link Share on Share on Share on Alert
	14 Feb 2025	Dr. Lal Pathlabs	Geojit BNP Paribas Target	1924.70	2954.00	2620.30 (-26.55%)	Target met	Accumulate	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Alert
	13 Jan 2025	Dr. Lal Pathlabs	Ventura	1924.70	2740.00	2863.80 (-32.79%)	Target met	Sell	pdf post cache	Broker Report DR. LAL PATHLABS LTD. Ventura Elevated Valuations Dampen Strong Fundamentals pdf Copy Link Share on Share on Share on Alert
	24 Oct 2024	Dr. Lal Pathlabs	ICICI Securities Limited Target	1924.70	3100.00	3049.10 (-36.88%)	Target met	Hold	pdf post cache	Broker Report Growth moderates; near term green shoots unlikely ICICI Securities Limited Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise. pdf Copy Link Share on Share on Share on Alert
	22 Aug 2024	Dr. Lal Pathlabs	Geojit BNP Paribas Reco Target	1924.70	3548.00	3306.50 (-41.79%)	Target met	Hold	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Alert
	08 Aug 2024	Dr. Lal Pathlabs	ICICI Securities Limited Target	1924.70	3240.00	3186.35 (-39.60%)	Target met	Hold	pdf post cache	Broker Report Steady quarter; valuation a bit pricey ICICI Securities Limited Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY. pdf Copy Link Share on Share on Share on Alert
	19 Jun 2024	Dr. Lal Pathlabs	Emkay	1924.70	2800.00	2679.15 (-28.16%)	Target met	Buy	pdf post cache	Broker Report Corner Office view: Spotlight on bundling and Suburban ramp up Emkay We met DLPL’s MD Dr. Om Manchanda to gauge competitive intensity and its strategy to boost volumes. Meeting KTAs are: 1) DLPL is increasingly witnessing the ‘bundling’ phenomenon as doctors are recommending multiple tests to ascertain accurate prognosis. pdf Copy Link Share on Share on Share on Alert
	10 May 2024	Dr. Lal Pathlabs	Emkay	1924.70	2800.00	2347.90 (-18.02%)	Target met	Buy	pdf post cache	Broker Report Swasthfit drives the beat Emkay DLPL posted a robust quarter, with revenue growing 11% YoY on the back of sample volume increasing 9% YoY and Swasthfit contributing 24% to the topline. pdf Copy Link Share on Share on Share on Alert
	08 Aug 2023	Dr. Lal Pathlabs	Geojit BNP Paribas Reco Target	1924.70	2110.00	2369.60 (-18.78%)	Target met	Sell	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Alert
	29 Jul 2023	Dr. Lal Pathlabs	ICICI Securities Limited Target	1924.70	2635.00	2354.65 (-18.26%)	Target met	Accumulate	pdf post cache	Broker Report Seasonality shrinks volumes though boost margins ICICI Securities Limited Dr Lal’s Pathlabs’ Q1 volume growth at 2.5% was impacted to some extent due to seasonality. Favourable test mix and traction in Swasthfit improved realisation per patient by 8.5% to INR 789 and aided gross margin expansion of 181bps YoY. pdf Copy Link Share on Share on Share on Alert
	10 Feb 2023	Dr. Lal Pathlabs	Geojit BNP Paribas Target	1924.70	2127.00	1966.40 (-2.12%)	Target met	Hold	pdf post cache	Broker Report DR. LAL PATHLABS LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Alert
more loading

New 52W High in past week

High vol. this week

Dr. Lal Pathlabs Ltd. share price target

Dr. Lal Pathlabs Ltd. has an average share price target of 1662.75. The consensus estimate represents a downside of -13.61% from the last price of 1924.70. View 5 reports from 4 analysts offering long-term price targets for Dr. Lal Pathlabs Ltd..

Spurt in high-value testing boosts performance; valuation pricey

US NDR KTAs – Secular growth trends reaffirmed

Strong quarter; upbeat FY27 guidance

Expanding Access to Advanced Diagnostics

DR. LAL PATHLABS LIMITED

DR. LAL PATHLABS LIMITED

FY25 AR: Stable outlook despite leadership transition

DR. LAL PATH LABS LTD.

Steady quarter; encouraging outlook

Decent quarter, limited headroom for margins expansion

DR. LAL PATHLABS LIMITED

DR. LAL PATHLABS LTD.

Growth moderates; near term green shoots unlikely

DR. LAL PATHLABS LIMITED

Steady quarter; valuation a bit pricey

Corner Office view: Spotlight on bundling and Suburban ramp up

Swasthfit drives the beat

DR. LAL PATHLABS LIMITED

Seasonality shrinks volumes though boost margins

DR. LAL PATHLABS LIMITED

Advisor Screeners